MX2012008603A - Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. - Google Patents
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.Info
- Publication number
- MX2012008603A MX2012008603A MX2012008603A MX2012008603A MX2012008603A MX 2012008603 A MX2012008603 A MX 2012008603A MX 2012008603 A MX2012008603 A MX 2012008603A MX 2012008603 A MX2012008603 A MX 2012008603A MX 2012008603 A MX2012008603 A MX 2012008603A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- gip agonist
- glucagon antagonist
- obesity
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan en la presente combinaciones de péptido que comprenden un péptido agonista de GIP y un péptido antagonista de glucagón. En algunas modalidades, la combinación de péptido se proporciona como una composición, por ejemplo, una composición farmacéutica, mientras que en otras modalidades, la combinación de péptido se proporciona como un equipo. En todavía otras modalidades, la combinación de péptido se proporciona como un conjugado, por ejemplo, un péptido de fusión, un heterodímero. En aspectos específicos, el péptido agonista de GIP es un análogo de glucagón humano natural. En aspectos específicos, el péptido antagonista de glucagón es un análogo de glucagón humano natural. En algunas modalidades, el péptido agonista de GIP se une covalentemente al péptido antagonista de glucagón por la vía de un enlazador. Además se proporcionan métodos para tratar una enfermedad, por ejemplo, un desorden metabólico, tal como diabetes y obesidad, que comprenden administrar las composiciones de péptido descritas en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29881210P | 2010-01-27 | 2010-01-27 | |
PCT/US2011/022608 WO2011094337A1 (en) | 2010-01-27 | 2011-01-26 | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012008603A true MX2012008603A (es) | 2013-01-25 |
Family
ID=44319749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008603A MX2012008603A (es) | 2010-01-27 | 2011-01-26 | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8551946B2 (es) |
EP (1) | EP2528618A4 (es) |
JP (2) | JP2013518115A (es) |
KR (1) | KR20120123443A (es) |
CN (1) | CN102834108A (es) |
BR (1) | BR112012018585A2 (es) |
CA (1) | CA2788304A1 (es) |
IN (1) | IN2012DN06437A (es) |
MX (1) | MX2012008603A (es) |
RU (1) | RU2012136450A (es) |
WO (1) | WO2011094337A1 (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
AU2008205229B2 (en) | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
EP2952202B1 (en) | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
US8975223B2 (en) | 2010-12-22 | 2015-03-10 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146 |
EP2718317B1 (en) * | 2011-06-10 | 2018-11-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
US10100097B2 (en) * | 2012-05-03 | 2018-10-16 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
CN104583234A (zh) | 2012-06-14 | 2015-04-29 | 赛诺菲 | 毒蜥外泌肽-4肽类似物 |
EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
CN104582736A (zh) * | 2012-06-21 | 2015-04-29 | 印第安纳大学研究及科技有限公司 | Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物 |
JP6300239B2 (ja) | 2012-06-21 | 2018-03-28 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
EA031852B1 (ru) | 2012-11-06 | 2019-03-29 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
BR112015014510A2 (pt) * | 2012-12-21 | 2017-11-21 | Sanofi Sa | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais |
US20160024169A1 (en) | 2013-03-14 | 2016-01-28 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
MX365465B (es) | 2013-03-21 | 2019-06-04 | Sanofi Aventis Deutschland | Sintesis de productos peptidicos que contienen imida ciclica. |
SG11201506804VA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of hydantoin containing peptide products |
AR095986A1 (es) | 2013-04-03 | 2015-11-25 | Sanofi Sa | Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas |
ES2900744T3 (es) * | 2013-05-28 | 2022-03-18 | Takeda Pharmaceuticals Co | Compuesto de péptidos |
WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
CN105745222A (zh) | 2013-10-17 | 2016-07-06 | 西兰制药公司 | 酰化胰高血糖素类似物 |
TWI670281B (zh) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Gip-glp-1雙重促效劑化合物及方法 |
CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
US9339482B2 (en) | 2013-11-22 | 2016-05-17 | Regents Of The University Of Minnesota | Methods to treat dysregulated blood glucose disorders |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
CN105440102B (zh) * | 2014-09-24 | 2018-09-25 | 中国科学院大连化学物理研究所 | 一种源于鹿皮的具有dpp-iv抑制活性的多肽及其应用 |
CN105504011B (zh) * | 2014-09-24 | 2018-09-25 | 中国科学院大连化学物理研究所 | 一种具有dpp-iv抑制活性的多肽及其在制备降血糖药物中的应用 |
CN105504008B (zh) * | 2014-09-24 | 2018-09-21 | 中国科学院大连化学物理研究所 | 一种具有dpp-iv抑制活性的鹿肽及其应用 |
WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
CN105504009B (zh) * | 2014-09-24 | 2018-10-09 | 中国科学院大连化学物理研究所 | 一种源于鹿筋的具有dpp-iv抑制活性的多肽及其应用 |
CN105504010B (zh) * | 2014-09-24 | 2018-09-21 | 中国科学院大连化学物理研究所 | 一种具有dpp-iv抑制活性的多肽及其应用 |
US10413593B2 (en) | 2014-10-24 | 2019-09-17 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
ES2883345T3 (es) * | 2014-10-29 | 2021-12-07 | Zealand Pharma As | Compuestos agonistas del GIP y métodos |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
JP6989385B2 (ja) | 2015-04-16 | 2022-01-05 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
TWI700291B (zh) * | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
MX2018007859A (es) | 2015-12-23 | 2018-11-09 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
CN108699125B (zh) * | 2015-12-31 | 2022-10-28 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂 |
SG11201806342SA (en) * | 2016-03-10 | 2018-08-30 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
EP3430033A4 (en) * | 2016-03-18 | 2019-11-20 | Merck Sharp & Dohme Corp. | CONJUGATES OF INSULIN-INCRETIN |
US20190290772A1 (en) * | 2016-06-02 | 2019-09-26 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1-t3 conjugates |
EP3463423A4 (en) * | 2016-06-02 | 2019-05-08 | Indiana University Research & Technology Corporation | GLUCAGON-T3 CONJUGATES |
GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
WO2018140857A2 (en) * | 2017-01-27 | 2018-08-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Bifunctional small peptide for autoimmune diabetes |
CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素(oxm)类似物及其应用 |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
US11590237B2 (en) | 2017-05-18 | 2023-02-28 | Merck Sharp & Dohme Llc | Pharmaceutical formulation comprising incretin-insulin conjugates |
PL3630806T3 (pl) * | 2017-05-31 | 2024-05-13 | The University Of Copenhagen | Analogi peptydów gip o długotrwałym działaniu |
CN108210988A (zh) * | 2018-03-08 | 2018-06-29 | 武汉职业技术学院 | 一种鱼皮胶原制备医用止血海绵的新工艺 |
IL277495B1 (en) * | 2018-03-23 | 2024-04-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
RU2020136305A (ru) | 2018-05-04 | 2022-05-05 | Ново Нордиск А/С | Производные gip и пути их применения |
TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
CN111825758A (zh) * | 2019-04-19 | 2020-10-27 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
CA3147770A1 (en) * | 2019-08-13 | 2021-02-18 | Jae Ha Ryu | Exenatide analog and use thereof |
WO2023016346A1 (zh) * | 2021-08-10 | 2023-02-16 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
AU2022400245A1 (en) | 2021-12-02 | 2024-05-30 | Københavns Universitet | Peptide-drug conjugates for treatment of neurodegenerative diseases |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
EP0628570A1 (en) | 1989-02-17 | 1994-12-14 | Chiron Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
WO1997029180A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
JP2000516912A (ja) | 1996-06-05 | 2000-12-19 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセンジン類似体、それらの製造方法およびそれらを含有する製剤 |
AU724326B2 (en) | 1996-09-09 | 2000-09-14 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
KR20010040819A (ko) | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | 제어방출형 제제 |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
DE69926007T2 (de) | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
WO2000034331A2 (en) | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
MXPA01009805A (es) | 1999-03-29 | 2004-07-30 | Univ Ulster | Peptido. |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
EP1356295A2 (en) | 2000-04-27 | 2003-10-29 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
WO2001096368A2 (en) | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
EP1695983B1 (en) | 2000-06-16 | 2009-03-04 | Eli Lilly & Company | Glucagon-like peptide-1 analogs |
CA2417100A1 (en) | 2000-08-02 | 2002-02-07 | Theratechnologies Inc. | Modified peptides with increased potency |
US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
EP1324779B1 (en) | 2000-09-29 | 2011-07-20 | Schering Corporation | Pegylated interleukin-10 |
US7199217B2 (en) | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
JP2005509409A (ja) | 2001-08-08 | 2005-04-14 | ジェンザイム・コーポレーション | 糖尿病および他の血糖疾患の治療方法 |
MXPA04001560A (es) | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
PL377687A1 (pl) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
WO2003035099A1 (en) | 2001-10-19 | 2003-05-01 | Eli Lilly And Company | Biphasic mixtures of glp-1 and insulin |
JP2005518408A (ja) | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用 |
WO2003058203A2 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
WO2003103572A2 (en) | 2002-06-04 | 2003-12-18 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
WO2003103697A2 (en) | 2002-06-11 | 2003-12-18 | Cell Therapeutics Scandinavia Ab | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
WO2003105760A2 (en) | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip) |
CA2497794A1 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
ATE458534T1 (de) | 2002-10-04 | 2010-03-15 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
US7329990B2 (en) | 2002-12-27 | 2008-02-12 | Lg Electronics Inc. | Plasma display panel having different sized electrodes and/or gaps between electrodes |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
SI1605897T1 (sl) | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
DK1620118T3 (da) | 2003-04-08 | 2014-09-29 | Yeda Res & Dev | Reversible pegylerede lægemidler |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP1633384B1 (en) | 2003-05-15 | 2012-03-14 | Trustees Of Tufts College | Stable analogs of glp-1 |
KR101293507B1 (ko) | 2003-06-03 | 2013-08-06 | 노보 노르디스크 에이/에스 | 안정화된 약학적 펩티드 조성물 |
JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
CN1802386B (zh) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
WO2004111078A2 (en) | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Compounds that modulate the glucagon response and uses thereof |
TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
AU2004298424A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel GLP-1 compounds |
US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
US7327408B1 (en) | 2004-11-15 | 2008-02-05 | Lightmaster Systems, Inc. | Illuminator that generates linearly polarized light for microdisplay based light engine |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
EP1863537A2 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
PL1881850T3 (pl) | 2005-05-13 | 2011-03-31 | Lilly Co Eli | Pegylowane związki GLP-1 |
WO2006134340A2 (en) | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
CA2622069A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
EP1937716A2 (en) | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
CA2638800A1 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
US20090054305A1 (en) | 2006-03-15 | 2009-02-26 | Novo Nordisk A/S | Mixtures of Amylin and Insulin |
CN101432025B (zh) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
EP2573111A1 (en) | 2006-04-20 | 2013-03-27 | Amgen Inc. | GLP-1 compounds |
WO2007133747A2 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN |
FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
WO2008021560A2 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
EP2069396B1 (en) | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
AU2008205229B2 (en) | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
EP2139458A4 (en) | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
MX2010001684A (es) | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
JP2010538049A (ja) | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー/エス | 切断型glp−1誘導体及びその治療的使用 |
WO2009035540A2 (en) | 2007-09-07 | 2009-03-19 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
CN101854948A (zh) | 2007-09-11 | 2010-10-06 | 诺沃-诺迪斯克有限公司 | 含有胰岛淀粉样多肽类和长效胰岛素的合剂 |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
CA2707861A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
WO2009099763A1 (en) * | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
NZ589847A (en) * | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
CA2852177A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
EP2952202B1 (en) * | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
AR074811A1 (es) * | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
US9044808B2 (en) | 2009-03-03 | 2015-06-02 | The Johns Hopkins University | System and method for precision transport, positioning, and assembling of longitudinal nano-structures |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
CA2797089A1 (en) * | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
WO2011163012A2 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
US8975223B2 (en) * | 2010-12-22 | 2015-03-10 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146 |
BR112013015389A2 (pt) * | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
US9044108B1 (en) | 2012-05-18 | 2015-06-02 | Roy G. Konrath | Combination storage and display system |
-
2011
- 2011-01-26 MX MX2012008603A patent/MX2012008603A/es not_active Application Discontinuation
- 2011-01-26 RU RU2012136450/10A patent/RU2012136450A/ru not_active Application Discontinuation
- 2011-01-26 EP EP11737598.0A patent/EP2528618A4/en not_active Withdrawn
- 2011-01-26 KR KR1020127021672A patent/KR20120123443A/ko not_active Application Discontinuation
- 2011-01-26 BR BR112012018585A patent/BR112012018585A2/pt not_active IP Right Cessation
- 2011-01-26 JP JP2012551270A patent/JP2013518115A/ja active Pending
- 2011-01-26 CN CN2011800170897A patent/CN102834108A/zh active Pending
- 2011-01-26 WO PCT/US2011/022608 patent/WO2011094337A1/en active Application Filing
- 2011-01-26 US US13/575,363 patent/US8551946B2/en not_active Expired - Fee Related
- 2011-01-26 CA CA2788304A patent/CA2788304A1/en not_active Abandoned
- 2011-01-26 IN IN6437DEN2012 patent/IN2012DN06437A/en unknown
-
2013
- 2013-09-13 US US14/026,671 patent/US9487571B2/en not_active Expired - Fee Related
-
2016
- 2016-05-19 JP JP2016100832A patent/JP2016183177A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016183177A (ja) | 2016-10-20 |
IN2012DN06437A (es) | 2015-10-09 |
US20140107021A1 (en) | 2014-04-17 |
US9487571B2 (en) | 2016-11-08 |
WO2011094337A8 (en) | 2012-08-16 |
WO2011094337A1 (en) | 2011-08-04 |
EP2528618A4 (en) | 2015-05-27 |
BR112012018585A2 (pt) | 2017-01-10 |
JP2013518115A (ja) | 2013-05-20 |
US20120322725A1 (en) | 2012-12-20 |
EP2528618A1 (en) | 2012-12-05 |
RU2012136450A (ru) | 2014-03-10 |
CN102834108A (zh) | 2012-12-19 |
KR20120123443A (ko) | 2012-11-08 |
US8551946B2 (en) | 2013-10-08 |
CA2788304A1 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012008603A (es) | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. | |
GEP20176629B (en) | Glucagon/glp-1 receptor co-agonists | |
MX345245B (es) | Polipeptidos manipulados que tienen duracion de accion incrementada. | |
EA020326B9 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения | |
PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
CL2008002111A1 (es) | Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras. | |
EA201171197A1 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
MX2012006406A (es) | Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos. | |
MX2013003419A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. | |
NZ606768A (en) | Pharmaceutical compositions and methods of treatment | |
NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
MX2009000900A (es) | Derivados de imidazolonas sustituidas, preparacion y usos. | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
MY156332A (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
EA201171074A1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
WO2014059384A3 (en) | ICAM-1 TARGETING ELPs | |
BR112013006651A2 (pt) | composição e cocristal de aprepitante l-prolina | |
UA112981C2 (uk) | Варіант людського gdnf | |
WO2009137436A3 (en) | Peptide conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |